Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

Al‐Samkari Hanny; Kuter David J.

首页> 外文期刊>British Journal of Haematology >Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

【24h】

Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

机译：血小板生成素受体激动剂的相对效力是慢性免疫血小板减少症的患者中的血小板受体激动剂的相气，Avatrombopag和Romiplostim

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《British Journal of Haematology》 |2018年第2期|共1页
作者
Al‐Samkari Hanny; Kuter David J.;
展开▼
作者单位

Center for HematologyMassachusetts General Hospital Cancer CenterBoston MA USA;

Center for HematologyMassachusetts General Hospital Cancer CenterBoston MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia [J] . Al‐Samkari Hanny, Kuter David J. British Journal of Haematology . 2018,第2期

机译：血小板生成素受体激动剂的相对效力是慢性免疫血小板减少症的患者中的血小板受体激动剂的相气，Avatrombopag和Romiplostim
2. Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials [J] . Bussel James B., Allen Lee F., Tian Wei, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：缺乏血浆胃生物标志物升高，具有慢性剂量的Avatrombopag，一种新的口服血小板蛋白受体激动剂，慢性免疫血小板减少患者在3期试验中
3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: Differential responses to eltrombopag and romiplostim: A case report and possible explanations [J] . AokiT., HaradaY., MatsubaraE., Journal of Clinical Pharmacy and Therapeutics . 2012,第6期

机译：难治性免疫性血小板减少症中的血小板生成素受体激动剂：对Eltrombopag和romiplostim的差异反应：病例报告和可能的解释
4. Discovery of a Ligand that Compensates for Decreased Endogenous Agonist Potency of Melanocortin-4 Receptor Polymorphisms Identified in Obese Humans [C] . Carrie Haskell-Luevano, Zhimin Xiang, Andrzej M. Wilczynski American Peptide Symposium . 2009

机译：发现肥胖人类中鉴定的黑素旋蛋白-4受体多态性的内源性激动剂效力降低的配体的发现
5. Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Healthy Subjects and Patients with Chronic Liver Disease [D] . NOMOTO, Maiko 2019

机译：阿法曲巴帕在健康受试者和慢性肝病患者中的药代动力学/药效学分析
6. Phase 3 randomised study of avatrombopag a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia [O] . Wojciech Jurczak, Krzysztof Chojnowski, Jiří Mayer, -1

机译：阿伐他莫巴（一种新的血小板生成素受体激动剂用于治疗慢性免疫性血小板减少症）的3期随机研究
7. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia [O] . Hanny Al-Samkari, David J. Kuter 2018

机译：血小板生成素受体激动剂的相对效力是慢性免疫血小板减少症的患者中的血小板受体激动剂的相气，Avatrombopag和Romiplostim

Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

著录项

相似文献

相关主题

期刊订阅